Skip to main content
. Author manuscript; available in PMC: 2014 Nov 19.
Published in final edited form as: J Urol. 2009 Feb 23;181(4):1635–1641. doi: 10.1016/j.juro.2008.11.109

Table 3.

Reasons for Ceasing Active Surveillance and Electing Treatment (n=43)*

Number (%)
Gleason ≥ 7 on surveillance biopsy 15 (35%)
Surveillance biopsy with > 3 cores or >50% in a single core 7 (16%)
Change in patient preference 6 (14%)
Rising PSA without worsening biopsy features 2 (5%)
MRI findings 2 (5%)
Voiding symptoms 1 (2%)
Bone metastases 1 (2%)
Upstaging via digital rectal examination 1 (2%)
Unknown 12 (28%)
*

Greater than 100% as some patients had multiple reasons